Dyslipidemia Market Report and Forecast 2025-2034
Description
The dyslipidemia market size was valued at USD 10.20 Billion in 2024 , driven by the emphasis on preventing cardiovascular diseases across the major markets. The market is expected to grow at a CAGR of 6.70% during the forecast period of 2025-2034, with the values likely to rise from USD 10.8 Billion in 2025 to USD 19.51 Billionby 2034 .
Dyslipidemia: Introduction
Dyslipidemia is a condition characterized by abnormal levels of lipids in the bloodstream. The most common forms of dyslipidemia involve high levels of bad cholesterol (LDL), triglycerides or low levels of good cholesterol (HDL). Untreated or severe dyslipidemia may lead to coronary artery disease (CAD) or peripheral artery disease (PAD). Based on cause, it can be categorized into two broad categories, primary dyslipidemia, which is inherited, and secondary dyslipidemia, which is caused by lifestyle factors. Treatment for dyslipidemia constitutes medications and lifestyle changes to control cholesterol levels naturally.
Dyslipidemia Market Analysis
The increasing development of drugs and new therapeutics to treat the condition are increasingly contributing to the dyslipidemia market share. Ezetimibe is frequently used in combination with statins and has shown significant reductions in LDL cholesterol levels. Alirocumab (Praluent) is a human immunoglobulin G1 monoclonal antibody while Evolocumab is another monoclonal G2 antibody belonging to PCSK9 category. Bempedoic acid is another key agent that decreases LDL-C levels and showcases evidence of good tolerability and safety.
With advanced research and ongoing clinical trials, scientists are also working on using the potential of ASOs to impact mRNA and provide new avenues for the treatment of persistent disorders. Therefore, there is hope for treating primary dyslipidemia as well, especially with the rising advances in gene therapies. Such efforts in research and development, along with increased support from governments and healthcare organizations are likely to aid the dyslipidemia market demand in the coming years.
Dyslipidemia Market Segmentation
Dyslipidemia Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Type Germany
France
Italy
Spain
United Kingdom
With the rising prevalence of obesity, sedentary lifestyle habits, unhealthy dietary changes and tobacco consumption, the United States is at a higher risk of developing cardiovascular diseases. As a result, the region is expected to lead the dyslipidemia market share in the forecast period. The existence of regulatory authorities such as the FDA plays a pivotal part in maintaining the quality and efficacy of drugs being launched in the market. This can be a major factor in the growing market value in the region.
Owing to a high percentage of the geriatric population, Europe is another major market for dyslipidemia. With a robust healthcare ecosystem as well as proactive government, there are several awareness and educational campaigns launched in the region, explaining the maintenance of a healthy heart. The market growth is further enhanced by the presence of key healthcare and academic institutions that continuously conduct clinical trials to determine the efficacy of treatments.
In Asia Pacific, the dyslipidemia market growth is certain with the increasing investment in healthcare research and development infrastructure. The region is witnessing numerous mergers and acquisitions between native and foreign companies that aim to leverage the academic expertise pertaining to the region while offering the latest technologies to develop quality solutions. In addition, the government is also aiding market growth by facilitating easy accessibility of relevant to the people in need at affordable prices.
Dyslipidemia Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Dyslipidemia: Introduction
Dyslipidemia is a condition characterized by abnormal levels of lipids in the bloodstream. The most common forms of dyslipidemia involve high levels of bad cholesterol (LDL), triglycerides or low levels of good cholesterol (HDL). Untreated or severe dyslipidemia may lead to coronary artery disease (CAD) or peripheral artery disease (PAD). Based on cause, it can be categorized into two broad categories, primary dyslipidemia, which is inherited, and secondary dyslipidemia, which is caused by lifestyle factors. Treatment for dyslipidemia constitutes medications and lifestyle changes to control cholesterol levels naturally.
Dyslipidemia Market Analysis
The increasing development of drugs and new therapeutics to treat the condition are increasingly contributing to the dyslipidemia market share. Ezetimibe is frequently used in combination with statins and has shown significant reductions in LDL cholesterol levels. Alirocumab (Praluent) is a human immunoglobulin G1 monoclonal antibody while Evolocumab is another monoclonal G2 antibody belonging to PCSK9 category. Bempedoic acid is another key agent that decreases LDL-C levels and showcases evidence of good tolerability and safety.
With advanced research and ongoing clinical trials, scientists are also working on using the potential of ASOs to impact mRNA and provide new avenues for the treatment of persistent disorders. Therefore, there is hope for treating primary dyslipidemia as well, especially with the rising advances in gene therapies. Such efforts in research and development, along with increased support from governments and healthcare organizations are likely to aid the dyslipidemia market demand in the coming years.
Dyslipidemia Market Segmentation
Dyslipidemia Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Type
- General dyslipidemia
- Hyperlipidemia
- Combined Hyperlipidemia
- Hypoalphalipoproteinemia
- Statin Drugs
- Non-Statin Lipid–Lowering Drugs
- Generic
- Branded
- Hospital Pharmacy
- Online pharmacy
- Retail Pharmacy
- Others
- Hospitals
- Homecare
- Specialty Clinics
- Others
- United States
- EU-4 and the United Kingdom
- Japan
With the rising prevalence of obesity, sedentary lifestyle habits, unhealthy dietary changes and tobacco consumption, the United States is at a higher risk of developing cardiovascular diseases. As a result, the region is expected to lead the dyslipidemia market share in the forecast period. The existence of regulatory authorities such as the FDA plays a pivotal part in maintaining the quality and efficacy of drugs being launched in the market. This can be a major factor in the growing market value in the region.
Owing to a high percentage of the geriatric population, Europe is another major market for dyslipidemia. With a robust healthcare ecosystem as well as proactive government, there are several awareness and educational campaigns launched in the region, explaining the maintenance of a healthy heart. The market growth is further enhanced by the presence of key healthcare and academic institutions that continuously conduct clinical trials to determine the efficacy of treatments.
In Asia Pacific, the dyslipidemia market growth is certain with the increasing investment in healthcare research and development infrastructure. The region is witnessing numerous mergers and acquisitions between native and foreign companies that aim to leverage the academic expertise pertaining to the region while offering the latest technologies to develop quality solutions. In addition, the government is also aiding market growth by facilitating easy accessibility of relevant to the people in need at affordable prices.
Dyslipidemia Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Pfizer, Inc.
- Novartis AG
- AstraZeneca plc
- Amgen, Inc.
- Abbott Laboratories.
- Bayer AG
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- Mylan N.V.
- Shionogi & Co., Ltd.
- Catabasis Pharmaceuticals
- DAIICHI SANKYO COMPANY, LIMITED
- Eli Lilly and Company
- GlaxoSmithKline plc
- ESPERION Therapeutics, Inc.
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Dyslipidemia Disease Overview
- 3.1 Guidelines and Stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Dyslipidemia Epidemiology Analysis – 7MM
- 5.1 7MM Epidemiology Scenario Overview (2018-2034)
- 5.2 United States Dyslipidemia Epidemiology Forecast (2018-2034)
- 5.3 EU-4 and United Kingdom Dyslipidemia Epidemiology Forecast (2018-2034)
- 5.3.1 Germany Dyslipidemia Epidemiology Forecast (2018-2034)
- 5.3.2 France Dyslipidemia Epidemiology Forecast (2018-2034)
- 5.3.3 Italy Dyslipidemia Epidemiology Forecast (2018-2034)
- 5.3.4 Spain Dyslipidemia Epidemiology Forecast (2018-2034)
- 5.3.5 United Kingdom Dyslipidemia Epidemiology Forecast (2018-2034)
- 5.4 Japan Dyslipidemia Epidemiology Forecast (2018-2034)
- 6 Dyslipidemia Market Overview – 7MM
- 6.1 Dyslipidemia Market Historical Value (2018-2024)
- 6.2 Dyslipidemia Market Forecast Value (2025-2034)
- 7 Dyslipidemia Market Landscape – 7MM
- 7.1 Dyslipidemia : Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Dyslipidemia Product Landscape
- 7.2.1 Analysis by End User
- 7.2.2 Analysis by Route of Administration
- 8 Dyslipidemia Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Dyslipidemia Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.3 Porter’s Five Forces Model
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Dyslipidemia Market Segmentation – 7MM
- 11.1 Dyslipidemia Market by Disease Type
- 11.1.1 Market Overview
- 11.1.2 General dyslipidemia
- 11.1.3 Hyperlipidemia
- 11.1.4 Combined hyperlipidemia
- 11.1.5 Hypoalphalipoproteinemia
- 11.2 Dyslipidemia Market by Drug Type
- 11.2.1 Market Overview
- 11.2.2 Statin Drugs
- 11.2.3 Non-Statin Lipid–Lowering Drugs
- 11.3 Dyslipidemia Market by Distribution Channel
- 11.3.1 Market Overview
- 11.3.2 Hospital Pharmacy
- 11.3.3 Online pharmacy
- 11.3.4 Retail Pharmacy
- 11.3.5 Others
- 11.4 Dyslipidemia Market by End User
- 11.4.1 Market Overview
- 11.4.2 Hospitals
- 11.4.3 Homecare
- 11.4.4 Specialty Clinics
- 11.4.5 Others
- 11.5 Dyslipidemia Market by Region
- 11.5.1 Market Overview
- 11.5.2 United States
- 11.5.3 EU-4 and the United Kingdom
- 11.5.3.1 Germany
- 11.5.3.2 France
- 11.5.3.3 Italy
- 11.5.3.4 Spain
- 11.5.3.5 United Kingdom
- 11.5.4 Japan
- 12 United States Dyslipidemia Market
- 12.1 Dyslipidemia Market Historical Value (2018-2024)
- 12.2 Dyslipidemia Market Forecast Value (2025-2034)
- 12.3 Dyslipidemia Market by Drug Type
- 12.4 Dyslipidemia Market by End User
- 13 EU-4 and United Kingdom Dyslipidemia Market
- 13.1 Dyslipidemia Market Historical Value (2018-2024)
- 13.2 Dyslipidemia Market Forecast Value (2025-2034)
- 13.3 Germany Dyslipidemia Market Overview
- 13.3.1 Dyslipidemia Market by Drug Type
- 13.3.2 Dyslipidemia Market by End User
- 13.4 France Dyslipidemia Market Overview
- 13.4.1 Dyslipidemia Market by Drug Type
- 13.4.2 Dyslipidemia Market by End User
- 13.5 Italy Dyslipidemia Market Overview
- 13.5.1 Dyslipidemia Market by Drug Type
- 13.5.2 Dyslipidemia Market by End User
- 13.6 Spain Dyslipidemia Market Overview
- 13.6.1 Dyslipidemia Market by Drug Type
- 13.6.2 Dyslipidemia Market by End User
- 13.7 United Kingdom Dyslipidemia Market Overview
- 13.7.1 Dyslipidemia Market by Drug Type
- 13.7.2 Dyslipidemia Market by End User
- 14 Japan Dyslipidemia Market
- 14.1 Dyslipidemia Market Historical Value (2018-2024)
- 14.2 Dyslipidemia Market Forecast Value (2025-2034)
- 14.3 Dyslipidemia Market by Drug Type
- 14.4 Dyslipidemia Market by End User
- 15 Regulatory Framework
- 15.1 Regulatory Overview
- 15.1.1 US FDA
- 15.1.2 EU EMA
- 15.1.3 JAPAN PMDA
- 16 Patent Analysis
- 16.1 Analysis by Type of Patent
- 16.2 Analysis by Publication year
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Patent Age
- 16.5 Analysis by CPC Analysis
- 16.6 Analysis by Patent Valuation
- 16.7 Analysis by Key Players
- 17 Grants Analysis
- 17.1 Analysis by year
- 17.2 Analysis by Amount Awarded
- 17.3 Analysis by Issuing Authority
- 17.4 Analysis by Grant Application
- 17.5 Analysis by Funding Institute
- 17.6 Analysis by NIH Departments
- 17.7 Analysis by Recipient Organization
- 18 Clinical Trials Analysis
- 18.1 Analysis by Trial Registration Year
- 18.2 Analysis by Trial Status
- 18.3 Analysis by Trial Phase
- 18.4 Analysis by Therapeutic Area
- 18.5 Analysis by Geography
- 19 Funding and Investment Analysis
- 19.1 Analysis by Funding Instances
- 19.2 Analysis by Type of Funding
- 19.3 Analysis by Funding Amount
- 19.4 Analysis by Leading Players
- 19.5 Analysis by Leading Investors
- 19.6 Analysis by Geography
- 20 Partnerships and Collaborations Analysis
- 20.1 Analysis by Partnership Instances
- 20.2 Analysis by Type of Partnership
- 20.3 Analysis by Leading Players
- 20.4 Analysis by Geography
- 21 Supplier Landscape
- 21.1 Pfizer, Inc.
- 21.1.1 Financial Analysis
- 21.1.2 Product Portfolio
- 21.1.3 Demographic Reach and Achievements
- 21.1.4 Mergers and Acquisitions
- 21.1.5 Certifications
- 21.2 Novartis AG
- 21.2.1 Financial Analysis
- 21.2.2 Product Portfolio
- 21.2.3 Demographic Reach and Achievements
- 21.2.4 Mergers and Acquisitions
- 21.2.5 Certifications
- 21.3 AstraZeneca plc
- 21.3.1 Financial Analysis
- 21.3.2 Product Portfolio
- 21.3.3 Demographic Reach and Achievements
- 21.3.4 Mergers and Acquisitions
- 21.3.5 Certifications
- 21.4 Amgen, Inc.
- 21.4.1 Financial Analysis
- 21.4.2 Product Portfolio
- 21.4.3 Demographic Reach and Achievements
- 21.4.4 Mergers and Acquisitions
- 21.4.5 Certifications
- 21.5 Abbott Laboratories
- 21.5.1 Financial Analysis
- 21.5.2 Product Portfolio
- 21.5.3 Demographic Reach and Achievements
- 21.5.4 Mergers and Acquisitions
- 21.5.5 Certifications
- 21.6 Bayer AG
- 21.6.1 Financial Analysis
- 21.6.2 Product Portfolio
- 21.6.3 Demographic Reach and Achievements
- 21.6.4 Mergers and Acquisitions
- 21.6.5 Certifications
- 21.7 Merck & Co., Inc.
- 21.7.1 Financial Analysis
- 21.7.2 Product Portfolio
- 21.7.3 Demographic Reach and Achievements
- 21.7.4 Mergers and Acquisitions
- 21.7.5 Certifications
- 21.8 Bristol-Myers Squibb Company
- 21.8.1 Financial Analysis
- 21.8.2 Product Portfolio
- 21.8.3 Demographic Reach and Achievements
- 21.8.4 Mergers and Acquisitions
- 21.8.5 Certifications
- 21.9 Mylan N.V.
- 21.9.1 Financial Analysis
- 21.9.2 Product Portfolio
- 21.9.3 Demographic Reach and Achievements
- 21.9.4 Mergers and Acquisitions
- 21.9.5 Certifications
- 21.10 Shionogi & Co., Ltd.
- 21.10.1 Financial Analysis
- 21.10.2 Product Portfolio
- 21.10.3 Demographic Reach and Achievements
- 21.10.4 Mergers and Acquisitions
- 21.10.5 Certifications
- 21.11 Catabasis Pharmaceuticals
- 21.11.1 Financial Analysis
- 21.11.2 Product Portfolio
- 21.11.3 Demographic Reach and Achievements
- 21.11.4 Mergers and Acquisitions
- 21.11.5 Certifications
- 21.12 DAIICHI SANKYO COMPANY, LIMITED
- 21.12.1 Financial Analysis
- 21.12.2 Product Portfolio
- 21.12.3 Demographic Reach and Achievements
- 21.12.4 Mergers and Acquisitions
- 21.12.5 Certifications
- 21.13 Eli Lilly and Company
- 21.13.1 Financial Analysis
- 21.13.2 Product Portfolio
- 21.13.3 Demographic Reach and Achievements
- 21.13.4 Mergers and Acquisitions
- 21.13.5 Certifications
- 21.14 GlaxoSmithKline plc
- 21.14.1 Financial Analysis
- 21.14.2 Product Portfolio
- 21.14.3 Demographic Reach and Achievements
- 21.14.4 Mergers and Acquisitions
- 21.14.5 Certifications
- 21.15 ESPERION Therapeutics, Inc.
- 21.15.1 Financial Analysis
- 21.15.2 Product Portfolio
- 21.15.3 Demographic Reach and Achievements
- 21.15.4 Mergers and Acquisitions
- 21.15.5 Certifications
- 22 Dyslipidemia Market- Distribution Model (Additional Insight)
- 22.1 Overview
- 22.2 Potential Distributors
- 22.3 Key Parameters for Distribution Partner Assessment
- 23 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 24 Company Competitiveness Analysis (Additional Insight)
- 24.1 Very Small Companies
- 24.2 Small Companies
- 24.3 Mid-Sized Companies
- 24.4 Large Companies
- 24.5 Very Large Companies
- 25 Payment Methods (Additional Insight)
- 25.1 Government Funded
- 25.2 Private Insurance
- 25.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
